Virus and immunotherapy combo shows promise for Hard-to-Treat cancers
NCT ID NCT03647163
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a combination of a modified virus (VSV-IFNβ-NIS) and immunotherapy drugs (pembrolizumab or ipilimumab+nivolumab) in people with advanced solid tumors, including non-small cell lung cancer, neuroendocrine carcinoma, and renal cell carcinoma. The virus is designed to infect and kill cancer cells while also boosting the immune system. The study aims to find the safest and most effective dose and to see if the combination can shrink tumors. About 33 participants are enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A modified virus (VSV-IFNβ-NIS) plus immunotherapy drugs (pembrolizumab or ipilimumab+nivolumab)
- What this could lead to
- If it works, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is an early-phase trial with only 33 participants, so results may not apply to everyone. The virus and immunotherapy combination can cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a Tumor's DNA guide better cancer care for kids?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?